Biotechnology
Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies
PISCATAWAY, N.J., Oct. 16, 2024 /PRNewswire/ -- The global cell and gene therapy (CGT) industry is poised for remarkable growth, driven by significant advances in life sciences and robust investments from capital markets. To strengthen this vital sector, GenScript is bringing together leading sc...
2024-10-16 17:43
1885
PharmAust affirms corporate strategy with name change to Neurizon Therapeutics
MELBOURNE, Australia, Oct. 15, 2024 /PRNewswire/ -- Neurizon Therapeutics Limited (ASX: NUZ) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing treatments for neurodegenerative diseases, is pleased to announce it has officially changed its name from PharmAust L...
2024-10-16 04:14
2521
Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting
SHENZHEN, China, Oct. 15, 2024 /PRNewswire/ -- On October 15, 2024, the list of selected candidates for the oral report of the American Association for the Study of the Liver (AASLD 2024) annual meeting was officially announced online. The abstract of the Phase II clinical study (CGZ203 trial) on...
2024-10-15 22:08
3030
Neurophet-AriBio to develop 'Next-Gen Platform for Alzheimer's diagnosis'
- Neurophet's brain MRI analysis technology incorporates fluid biomarker data from AriBio's global Phase 3 clinical trial for Alzheimer's disease - Collaborates leveraging Neurophet's medical image analysis technology and AriBio's clinical trial data analysis expertise SEOUL, South Korea, Oct. 1...
2024-10-15 21:00
2142
Bloomage Debuts New Products at CPHI Milan to Reinforce Its Commitment to Innovation
MILAN, Oct. 15, 2024 /PRNewswire/ -- Bloomage, a global leader in hyaluronic acid and other bioactive substance innovations, unveiled its Hyatrue® Sterile Sodium Hyaluronate (HA) and showcased its BloomseaN™ Polydeoxyribonucleotide (PDRN) and Polynucleotide (PN) at CPHI Milan. Known to be at "the...
2024-10-15 21:00
1418
PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration
* Safety Review Committee (SRC) approves single ascending dose 4mg cohort in Phase 1 trial of PMC-403, preparing for multiple ascending dose 4 mg cohort. * PMC-403 is being explored in broader therapeutic areas, including rare vascular disease systemic capillary leak syndrome (SCLS) and kidney...
2024-10-15 09:51
2345
Illuma, Global Pioneer in HMO Research, Launches Traceability Journey in Switzerland, Unveiling Next-Generation HMO Innovations
VEVEY, Switzerland, Oct. 14, 2024 /PRNewswire/ -- Recently at Nestlé's headquarters inVevey, Switzerland, illuma, a global super premium brand of maternal and infant nutrition under Nestlé, began its "Human Milk Oligosaccharides (HMO) Research Traceability Journey". With a focus on the most rece...
2024-10-14 23:31
2136
Tsingke Shines at Cell & Gene Therapy International 2024
BEIJING and BOSTON, Oct. 14, 2024 /PRNewswire/ -- Beijing Tsingke Biotech Co., Ltd. recently concluded a successful exhibition at CGTI2024 inBoston. This premier event attracted over 3,200 global attendees, including professionals from the top 20 biopharma companies. Tsingke showcased its innovat...
2024-10-14 20:11
2282
Samsung Biologics launches high-concentration formulation platform to accelerate high-dose drug development
* S-HiConTM is designed to maximize drug delivery and stability through high-concentration formulation * The platform can address challenges associated with viscosity and achieve stable liquid formulation for over 200 mg/mL subcutaneous administration INCHEON, South Korea, Oct. 14, 2024 /PRNe...
2024-10-14 19:00
2818
US FDA issues Study May Proceed letter for the Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors, Sponsored by the US National Cancer Institute
TAIPEI and SAN DIEGO, Oct. 14, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that FDA issues Study May Proceed letter for its developing drug Pid...
2024-10-14 19:00
3305
21st TAITA Annual Conference Explores Taiwan's AI Era Strategies in the Global Tech Supply Chain
TAIPEI, Oct. 13, 2024 /PRNewswire/ -- The upcoming 21st TAITA-SV Annual Conference, scheduled forSaturday, October 19, 2024, at the Hyatt Regency Hotel inSanta Clara, California, will focus on the theme "Taiwan's Strategic Layout in the AI Era." The conference will explore howTaiwan leverages its...
2024-10-14 10:32
2183
Sunvozertinib Granted Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Fourth Breakthrough Therapy Designation for sunvozertinib in NSCLC with EGFR exon20ins SHANGHAI, Oct. 13, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the Center...
2024-10-13 16:04
3284
Ailux Biologics, a Division of XtalPi, Enters into a License Agreement with Janssen Biotech on Biologics AI Platform
CAMBRIDGE, Mass., Oct. 12, 2024 /PRNewswire/ -- XtalPi, a global leader in AI drug discovery, announced today a license agreement between Ailux Biologics, a division of XtalPi Inc., and Janssen Biotech, Inc.,(Janssen) a Johnson & Johnson company, on one of its proprietary biologics AI platforms. ...
2024-10-12 16:57
5390
Baird Medical Announces Preliminary Financial Results for the Six Months Ended June 30, 2024
Total revenues increased to US$13.1 million, representing 13.8% year-over-year growth Net income reached US$4.4 million, representing 85.8% year-over-year growth GUANGZHOU, China, Oct. 11, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"...
2024-10-11 20:00
5486
GenScript Biotech Advances Sustainable Development with MSCI ESG Rating Upgrade to A
PISCATAWAY, N.J., Oct. 11, 2024 /PRNewswire/ -- GenScript Biotech Corporation has recently been upgraded to an A rating in its Environmental, Social, and Governance (ESG) score by MSCI, a globally recognized rating agency. This upgrade reflects GenScript's unwavering commitment to integrating su...
2024-10-11 17:09
3427
Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Oct. 9, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunolo...
2024-10-10 11:04
2358
Arbele Announces Strategic Collaborations on AI Precision Oncology and Manufacturing to Advance CDH17-Targeted Immunotherapeutics
SEATTLE, Oct. 9, 2024 /PRNewswire/ -- Arbele, a leading innovator in biopharmaceutical & biotechnology focused on targeting cadherin-17 (CDH17), is pleased to announce strategic collaborations in precision oncology using artificial intelligence (AI) to advance targeted immunotherapeutics of bisp...
2024-10-09 23:00
2217
Nona Biosciences Enters Strategic Collaboration with OverT Bio to Advance Next-Generation Cell Therapies for Solid Tumors
CAMBRIDGE, Mass., Oct. 9, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), today announced a strategic collaboration with OverT Bio, aNew York-based biotechnology company. The collaboration will focus on developing ne...
2024-10-09 20:00
2079
Alpha Fusion Accelerates Astatine-based Drug Discovery with Series B Funding
OSAKA, Japan, Oct. 9, 2024 /PRNewswire/ -- Alpha Fusion, Inc. (CEO: Sunao Fujioka, headquartered in Kita-ku, Osaka), has raised a total of ¥1.02 billion through a Series B funding round. The round was led by SBI Investment Co., Ltd. andOSAKA University Venture Capital, with participation from sev...
2024-10-09 15:23
2177
The CDE has Granted Breakthrough Therapy Designation to LBL-024, a Bispecific Antibody that Targets PD-L1 and 4-1BB, Developed by Leads Biolabs, for the Treatment of Extrapulmonary Neuroendocrine Carcinoma.
NANJING, China, Oct. 9, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") announced that Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation to LBL-024, an anti-PD-L1/4-1BB bispecific antibody indepe...
2024-10-09 13:32
2062
Week's Top Stories
Most Reposted
Agoda Establishes Strategic Partnership with Taipei City Government, Promoting International Tourism Development
[Picked up by 312 media titles]
2026-04-16 17:15
Hai Robotics and Maersk Redefine Fashion Fulfilment with High-Density Robotics at 10-Metre Scale in Singapore
[Picked up by 298 media titles]
2026-04-14 10:00
Blaize and Winmate Announce Strategic Collaboration to Advance Sovereign Edge AI Capabilities for Defense and Critical Infrastructure
[Picked up by 296 media titles]
2026-04-16 18:00
One Bangkok Hosted "Sunsational Songkran Festival 2026"
[Picked up by 289 media titles]
2026-04-16 15:34
Silicon Box Announces It Joins Imec Automotive Chiplet Program to Strengthen Chip Supply Chains for Next-Generation Vehicles
[Picked up by 288 media titles]
2026-04-15 21:02
Most Read
Blaize Announces Expected First Quarter 2026 Revenue and Newly Awarded Contract with NeoTensr Anticipated to Generate $50.0 Million in Revenue
2026-04-14 21:43
6195
NYSE Content Update: U.S.-Based Diversified Energy to Ring Bell for 25 Years Since its Founding
2026-04-13 21:06
5650
Makerfire Adopts Breakthrough USX51 Industrial-Grade AI Flight Controller: Empowering Enterprises to Cut Costs and Boost Efficiency in Low-Altitude Operations
2026-04-11 01:00
5508
OCI Global Publishes 2025 Annual Report and Audited Financial Statements
2026-04-11 00:49
5001